期刊
JOURNAL OF CLINICAL INVESTIGATION
卷 123, 期 8, 页码 3190-3200出版社
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI70212
关键词
-
资金
- EU-Marie Curie PIEF
- Deutsche Krebshilfe
- Deutsche Forschungsgemeinschaft (DFG)
- Hamburg Excellence Initiative (LEXI)
- Hamburger Krebsgesellschaft
- Roggenbuck Stiftung
- Flemish Government
- Leducq Transatlantic Network
- Belgian Science Policy IAP7
- DFG [SFB834, Exc147-1]
- ERC
Four decades ago, angiogenesis was recognized as a therapeutic target for blocking cancer growth. Because of its importance, VEGF has been at the center stage of antiangiogenic therapy. Now, several years after FDA approval of an anti-VEGF antibody as the first antiangiogenic agent, many patients with cancer and ocular neovascularization have benefited from VEGF-targeted therapy; however, this anticancer strategy is challenged by insufficient efficacy, intrinsic refractoriness, and resistance. Here, we examine recent discoveries of new mechanisms underlying arigiogenesis, discuss successes and challenges of current antiangiogenic therapy, and highlight emerging antiangiogenic paradigms.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据